Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dasatinib

FDA-approved product (tablet, oral), marketed as Dasatinib, Phyrago, Sprycel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dasatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Cancer
  • Childhood acute lymphoblastic leukemia
  • Childhood cancer
  • Chronic myelogenous leukemia
  • Lymphoblastic lymphoma
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dasatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dasatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

    NCT01173679 · start 2010-07

    Registered record
    Registry ID
    NCT01173679
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    dasatinib; Rituximab; fludarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2015-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventiondasatinib; Rituximab; fludarabine
    PhasePhase 2
    Registry statusTerminated

  • Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

    NCT01310010 · start 2010-04

    Registered record
    Registry ID
    NCT01310010
    Conditions
    Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2016-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
    Interventiondasatinib
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Response of Dasatinib to Treat Mastocytosis

    NCT00979160 · start 2009-11

    Registered record
    Registry ID
    NCT00979160
    Conditions
    Systemic Mastocytosis
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-11
    Completion
    2012-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Mastocytosis
    InterventionDasatinib
    PhasePhase 2
    Registry statusUnknown

  • Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

    NCT01015222 · start 2009-11

    Registered record
    Registry ID
    NCT01015222
    Conditions
    Advanced Cancer
    Interventions
    Dasatinib; Bevacizumab; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2021-05-27
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionDasatinib; Bevacizumab; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

    NCT00700882 · start 2009-07-02

    Registered record
    Registry ID
    NCT00700882
    Conditions
    Melanoma (Skin)
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07-02
    Completion
    2020-12-28
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventiondasatinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    NCT00918463 · start 2009-06

    Registered record
    Registry ID
    NCT00918463
    Conditions
    Diffuse Large B-cell Lymphoma
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2011-05-23
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma
    Interventiondasatinib
    PhasePhase 2
    Registry statusTerminated

  • An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

    NCT00903734 · start 2009-04

    Registered record
    Registry ID
    NCT00903734
    Conditions
    Advanced Cancers
    Interventions
    Erlotinib Hydrochloride (Tarceva)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers
    InterventionErlotinib Hydrochloride (Tarceva)
    PhasePhase 1
    Registry statusCompleted

  • A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

    NCT00777036 · start 2009-03-20

    Registered record
    Registry ID
    NCT00777036
    Conditions
    Leukemia
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03-20
    Completion
    2025-01-27
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionDasatinib
    PhasePhase 2
    Registry statusCompleted

  • Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

    NCT00858403 · start 2009-03

    Registered record
    Registry ID
    NCT00858403
    Conditions
    Lung Cancer
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-03
    Completion
    2010-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionDasatinib
    PhasePhase 2
    Registry statusTerminated

  • Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

    NCT00860158 · start 2009-03

    Registered record
    Registry ID
    NCT00860158
    Conditions
    Prostate Cancer
    Interventions
    Dasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy
    PhasePhase 2
    Registry statusTerminated

  • Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

    NCT00764309 · start 2009-01

    Registered record
    Registry ID
    NCT00764309
    Conditions
    Scleroderma
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-04
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScleroderma
    Interventiondasatinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

    NCT00788125 · start 2008-09-03

    Registered record
    Registry ID
    NCT00788125
    Conditions
    Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    carboplatin; dasatinib; etoposide phosphate; ifosfamide; microarray analysis; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; therapeutic conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2008-09-03
    Completion
    2022-07-30
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer +7 more
    Interventioncarboplatin; dasatinib; etoposide phosphate; ifosfamide +6 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

    NCT00688766 · start 2008-08

    Registered record
    Registry ID
    NCT00688766
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    retaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2009-05
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    Interventionretaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    PhasePhase 3
    Registry statusTerminated

  • The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

    NCT00655746 · start 2008-04

    Registered record
    Registry ID
    NCT00655746
    Conditions
    Healthy
    Interventions
    Dasatinib + Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-04
    Completion
    2008-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDasatinib + Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

    NCT00439270 · start 2007-07

    Registered record
    Registry ID
    NCT00439270
    Conditions
    Metastatic Prostate Cancer
    Interventions
    Dasatinib; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2013-01
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionDasatinib; Docetaxel
    PhasePhase 1 / Phase 2
    Registry statusCompleted